In order to solve challenges of global health, organizations of all types must come together to collaborate and report results. IDRI is part of an organization called Alliance for Case Studies for Global Health that brings together stakeholders to prepare multi-sector case studies to identify ways in which global health concerns are being addressed. These case studies describe relationships, lessons learned and next steps along the way to improving global health.

Other members of the Alliance include the Bill & Melinda Gates Foundation, Biotechnology Industry Organization (BIO), Global Health Progress (GHP), International AIDS Vaccine Initiative (IAVI), Association of University Technology Managers (AUTM) and World Health Organization's Special Programme for Research and Training in Tropical Diseases (TDR).

IDRI is featured in four cases studies published by the Alliance. Please read more to learn about our role in improving global health.

- **Expertise and Partnerships Combine to Restart the Tuberculosis Pipeline:** "The tuberculosis bacterium is an extremely difficult bug to work with," says Tanya Parish, Ph.D., vice president of drug discovery at IDRI.

- **IDRI's Campaign to Eliminate Leprosy:** Malcolm Duthie, Ph.D., of IDRI says, "The WHO-MDT campaign drove the numbers down to 250,000 cases a year, but that number has not changed in nearly a decade. It's clear that current detection methods and treatment are not going to eliminate this disease completely."

- **Man and Dog -- Working Toward a Vaccine and New Diagnostic Test for Leishmaniasis:** "We must control the dog disease to control the human disease," says Antonio Campos-Neto, M.D., Ph.D., head of the Department of Cytokine Biology at the Forsyth Institute, which is coordinating a two-part canine vaccine trial with IDRI.

- **Vaccine-Development Collaborations Strengthen Ability to Respond to Pandemics:** "Modern vaccines are so pure that they may not activate a sufficient immune response. That's where adjuvants come in. They trigger and enhance the immune response. In fact, they do much more," says Darrick Carter, Ph.D., vice president for adjuvant technology at IDRI.

**Contacts:**
IDRI: Lee Schoentrup | 206.858.6064 | media@idri.org

Please note: not all opinions stated in these articles are necessarily reflective of IDRI’s opinions.